File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Oncological Efficacy of ALPPS for Early-Staged Hepatocellular Carcinoma
Title | Oncological Efficacy of ALPPS for Early-Staged Hepatocellular Carcinoma |
---|---|
Authors | |
Issue Date | 2019 |
Publisher | S. Karger AG. The Journal's web site is located at http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=255487 |
Citation | The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019), Sapporo, Japan, 29-31 August 2019. In Liver Cancer, 2019, v. 8 n. Suppl. 1, p. 24 How to Cite? |
Abstract | ALPPS has been advocated for future liver remnant (FLR) augmentation in liver metastasis or non-cirrhotic liver tumors in recent years. Data on the effect of ALPPS in chronic hepatitis or cirrhosis-related early HCC remained scarce. The aim of this study was to evaluate the long-term outcome of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for earlystaged hepatitis-related hepatocellular carcinoma (HCC) in comparison with
portal vein embolization (PVE). From 2002 to 2018, 148 patients with HCC (hepatitis B: n = 136, 92.0%) underwent FLR modulation (ALPPS, n = 46; PVE: n = 102). Among those who had resections, 65 patients (56.5%) had cirrhosis. ALPPS induced absolute FLR volume increment by 48.8%, or FLR estimated total liver volume ratio by 12.8% over 6 days. When stratified according to tumor stages, the 1-, 3-, and 5-year OS rates for stage I/II for ALPPS (n = 17) were 81.4%,
69.8%, and 58.2%, and the corresponding rates for PVE (n = 43) were 93%, 85.5%, and 74.5%, respectively (P = 0.183). The 1, 3, and 5-year DFS rates for stage I/II for ALPPS were 81.4%, 54.3%, and 40.7%, and the corresponding rates for PVE were 74.3%, 53.8%, and 53.8% (P = 0.664). In conclusion, ALPPS conferred comparable and long-term oncological outcome with PVE for earlystaged HCC. |
Description | Symposium 3: Optimal Therapy for Small HCC (Resection vs. RFA) - no. S3-2 |
Persistent Identifier | http://hdl.handle.net/10722/311110 |
ISSN | 2023 Impact Factor: 11.6 2023 SCImago Journal Rankings: 3.599 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, ACY | - |
dc.date.accessioned | 2022-03-04T08:41:02Z | - |
dc.date.available | 2022-03-04T08:41:02Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019), Sapporo, Japan, 29-31 August 2019. In Liver Cancer, 2019, v. 8 n. Suppl. 1, p. 24 | - |
dc.identifier.issn | 2235-1795 | - |
dc.identifier.uri | http://hdl.handle.net/10722/311110 | - |
dc.description | Symposium 3: Optimal Therapy for Small HCC (Resection vs. RFA) - no. S3-2 | - |
dc.description.abstract | ALPPS has been advocated for future liver remnant (FLR) augmentation in liver metastasis or non-cirrhotic liver tumors in recent years. Data on the effect of ALPPS in chronic hepatitis or cirrhosis-related early HCC remained scarce. The aim of this study was to evaluate the long-term outcome of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for earlystaged hepatitis-related hepatocellular carcinoma (HCC) in comparison with portal vein embolization (PVE). From 2002 to 2018, 148 patients with HCC (hepatitis B: n = 136, 92.0%) underwent FLR modulation (ALPPS, n = 46; PVE: n = 102). Among those who had resections, 65 patients (56.5%) had cirrhosis. ALPPS induced absolute FLR volume increment by 48.8%, or FLR estimated total liver volume ratio by 12.8% over 6 days. When stratified according to tumor stages, the 1-, 3-, and 5-year OS rates for stage I/II for ALPPS (n = 17) were 81.4%, 69.8%, and 58.2%, and the corresponding rates for PVE (n = 43) were 93%, 85.5%, and 74.5%, respectively (P = 0.183). The 1, 3, and 5-year DFS rates for stage I/II for ALPPS were 81.4%, 54.3%, and 40.7%, and the corresponding rates for PVE were 74.3%, 53.8%, and 53.8% (P = 0.664). In conclusion, ALPPS conferred comparable and long-term oncological outcome with PVE for earlystaged HCC. | - |
dc.language | eng | - |
dc.publisher | S. Karger AG. The Journal's web site is located at http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=255487 | - |
dc.relation.ispartof | The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019) | - |
dc.relation.ispartof | Liver Cancer | - |
dc.rights | Liver Cancer. Copyright © S. Karger AG. | - |
dc.title | Oncological Efficacy of ALPPS for Early-Staged Hepatocellular Carcinoma | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Chan, ACY: acchan@hku.hk | - |
dc.identifier.authority | Chan, ACY=rp00310 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.hkuros | 320085 | - |
dc.identifier.partofdoi | 10.1159/000502497 | - |
dc.identifier.issnl | 1664-5553 | - |